Clinical trials: Inflammatory Disease Activity
Psoriatic Arthritis
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.
- Trial name
- PALACE 3 (NCT01212770)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 505 people
- Sponsor
- Amgen
Crohn's Disease
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
- Trial name
- NCT02425111
- Testing
- Vedolizumab
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Takeda
Crohn's Disease
A Study To Monitor Long-Term Treatment With PF-00547659
This study provides open-label drug to eligible patients who have completed a prior study of PF-00547659. The primary endpoint for this study is long-term safety.
- Trial name
- OPERA II (NCT01298492)
- Testing
- PF-00547659
- Where
- 112 sites in United States, Austria and 13 more
- Volunteers
- 268 people
- Sponsor
- Shire
Crohn Disease
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week…
- Trial name
- PRISM (NCT04102111)
- Testing
- JNJ-67864238
- Where
- 63 sites in United States, Argentina and 5 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
Dysbiosis, Endotoxemia
Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults.
- Conditions
- Dysbiosis, Endotoxemia, Metabolic Syndrome, Inflammation
- Trial name
- NCT03973996
- Testing
- Green Tea Extract
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Ulcerative Colitis
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
- Trial name
- NCT02447302
- Testing
- Etrasimod
- Where
- 134 sites in United States, Australia and 19 more
- Volunteers
- 156 people
- Sponsor
- Arena Pharmaceuticals
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT04987307
- Testing
- Efavaleukin alfa
- Where
- 200 sites in United States, Argentina and 24 more
- Volunteers
- 221 people
- Sponsor
- Amgen
Crohn's Disease
A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease (CD).
- Trial name
- HarbOR (NCT02976129)
- Testing
- V565
- Where
- 94 sites in United States, Austria and 11 more
- Volunteers
- 125 people
- Sponsor
- VHsquared Ltd.
Ulcerative Colitis
Open-label Extension Study of Brazikumab in Ulcerative Colitis
The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term…
- Trial name
- Expedition (NCT04277546)
- Testing
- Brazikumab Maintenance Dose, Brazikumab Induction Dose
- Where
- 36 sites in United States, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to…
- Trial name
- NCT03518086
- Testing
- Mirikizumab
- Where
- 502 sites in United States, Argentina and 33 more
- Volunteers
- 1,281 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if…
- Trial name
- NCT00771667
- Testing
- Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP)
- Where
- 174 sites in United States, Australia and 10 more
- Volunteers
- 526 people
- Sponsor
- Centocor, Inc.
Ulcerative Colitis (UC)
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis…
- Trial name
- U-Accomplish (NCT03653026)
- Testing
- Upadacitinib
- Where
- 379 sites in United States, Argentina and 42 more
- Volunteers
- 522 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Crohn's Disease
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.
- Trial name
- NCT03104413
- Testing
- risankizumab SC, risankizumab IV
- Where
- 403 sites in United States, Argentina and 41 more
- Volunteers
- 618 people
- Sponsor
- AbbVie
Colitis, Ulcerative
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
- Trial name
- NCT02497469
- Testing
- Vedolizumab, Adalimumab
- Where
- 330 sites in United States, Argentina and 32 more
- Volunteers
- 771 people
- Sponsor
- Takeda
Inflammatory Bowel Disease
A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease
The purpose of this study is to measure IL-6 and IL-6/sIL-6R complex levels in subjects with active moderate to severe ulcerative colitis or Crohn's disease.
- Trial name
- NCT02790281
- Testing
- Blood sampling
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 33 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT02895100
- Testing
- PTG-100
- Where
- 98 sites in United States, Australia and 15 more
- Volunteers
- 98 people
- Sponsor
- Protagonist Therapeutics, Inc.
Colitis, Ulcerative
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative…
- Trial name
- NCT01100112
- Testing
- Budesonide
- Where
- 15 sites in India
- Volunteers
- 61 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis, Digestive System Diseases
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC)…
- Conditions
- Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis
- Trial name
- NCT02647866
- Testing
- KHK4083
- Where
- 23 sites in United States, Czechia and 5 more
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin, Inc.